Armata Pharmaceuticals Extends Credit Agreement and CMO Departs
Company Announcements

Armata Pharmaceuticals Extends Credit Agreement and CMO Departs

Armata Pharmaceuticals ( (ARMP) ) just unveiled an update.

The Company recently amended its Credit and Convertible Credit Agreements, extending their maturity dates to January 2026, a move that could impact its financial strategy. Concurrently, the Company announced the departure of its Chief Medical Officer, Mina Pastagia, offering her a severance package as they finalize her separation terms. These developments highlight significant operational and financial shifts for the Company.

Learn more about ARMP stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyArmata Pharmaceuticals reports Q3 EPS (15c) vs. (86c) last year
TipRanks Auto-Generated NewsdeskArmata Completes Enrollment for Innovative Bacteriophage Study
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App